Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DUO-E: Durvalumab with or without Olaparib in Endometrial Cancer
NCT04269200Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2020
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 22
01
Overview
A Phase 3 trial of durvalumab, olaparib in endometrial cancer (EC), sponsored by AstraZeneca. Started May 2020; status: active, not recruiting.
02
Drugs
durvalumabolaparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT04269200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04269200.